Is targeted therapy feasible in acute myelogenous leukemia?

Heiko Konig, Mark Levis

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

The prognosis for patients with acute myeloid leukemia (AML) is determined to a large degree by the biology of the leukemic cell. In recent years, the identification and characterization of genetic aberrations has vastly improved our understanding of the pathogenesis of AML. In contrast, however, there has been a lack of clinically meaningful therapeutic advances. The same chemotherapeutic strategies have been applied to AML for several decades now, and while these regimens are effective in inducing remission, most patients relapse within months after initial treatment. Hence, there is an urgent need for novel therapies. We review herein a number of lines of laboratory and clinical trial data supporting the clinical value of targeted treatment approaches that will likely result in improved outcomes for patients with AML.

Original languageEnglish (US)
Pages (from-to)118-127
Number of pages10
JournalCurrent Hematologic Malignancy Reports
Volume9
Issue number2
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Acute Myeloid Leukemia
Therapeutics
Cell Biology
Clinical Trials
Recurrence

Keywords

  • Acute myelogenous leukemia
  • Chemotherapeutic strategies
  • Molecular markers
  • Pathogenesis
  • Relapse

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research
  • Medicine(all)

Cite this

Is targeted therapy feasible in acute myelogenous leukemia? / Konig, Heiko; Levis, Mark.

In: Current Hematologic Malignancy Reports, Vol. 9, No. 2, 2014, p. 118-127.

Research output: Contribution to journalReview article

@article{41f022e3f6ea4c728901cb1cbebdddd8,
title = "Is targeted therapy feasible in acute myelogenous leukemia?",
abstract = "The prognosis for patients with acute myeloid leukemia (AML) is determined to a large degree by the biology of the leukemic cell. In recent years, the identification and characterization of genetic aberrations has vastly improved our understanding of the pathogenesis of AML. In contrast, however, there has been a lack of clinically meaningful therapeutic advances. The same chemotherapeutic strategies have been applied to AML for several decades now, and while these regimens are effective in inducing remission, most patients relapse within months after initial treatment. Hence, there is an urgent need for novel therapies. We review herein a number of lines of laboratory and clinical trial data supporting the clinical value of targeted treatment approaches that will likely result in improved outcomes for patients with AML.",
keywords = "Acute myelogenous leukemia, Chemotherapeutic strategies, Molecular markers, Pathogenesis, Relapse",
author = "Heiko Konig and Mark Levis",
year = "2014",
doi = "10.1007/s11899-014-0198-1",
language = "English (US)",
volume = "9",
pages = "118--127",
journal = "Current Hematologic Malignancy Reports",
issn = "1558-8211",
publisher = "Springer Science + Business Media",
number = "2",

}

TY - JOUR

T1 - Is targeted therapy feasible in acute myelogenous leukemia?

AU - Konig, Heiko

AU - Levis, Mark

PY - 2014

Y1 - 2014

N2 - The prognosis for patients with acute myeloid leukemia (AML) is determined to a large degree by the biology of the leukemic cell. In recent years, the identification and characterization of genetic aberrations has vastly improved our understanding of the pathogenesis of AML. In contrast, however, there has been a lack of clinically meaningful therapeutic advances. The same chemotherapeutic strategies have been applied to AML for several decades now, and while these regimens are effective in inducing remission, most patients relapse within months after initial treatment. Hence, there is an urgent need for novel therapies. We review herein a number of lines of laboratory and clinical trial data supporting the clinical value of targeted treatment approaches that will likely result in improved outcomes for patients with AML.

AB - The prognosis for patients with acute myeloid leukemia (AML) is determined to a large degree by the biology of the leukemic cell. In recent years, the identification and characterization of genetic aberrations has vastly improved our understanding of the pathogenesis of AML. In contrast, however, there has been a lack of clinically meaningful therapeutic advances. The same chemotherapeutic strategies have been applied to AML for several decades now, and while these regimens are effective in inducing remission, most patients relapse within months after initial treatment. Hence, there is an urgent need for novel therapies. We review herein a number of lines of laboratory and clinical trial data supporting the clinical value of targeted treatment approaches that will likely result in improved outcomes for patients with AML.

KW - Acute myelogenous leukemia

KW - Chemotherapeutic strategies

KW - Molecular markers

KW - Pathogenesis

KW - Relapse

UR - http://www.scopus.com/inward/record.url?scp=84903597457&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903597457&partnerID=8YFLogxK

U2 - 10.1007/s11899-014-0198-1

DO - 10.1007/s11899-014-0198-1

M3 - Review article

C2 - 24599573

AN - SCOPUS:84903597457

VL - 9

SP - 118

EP - 127

JO - Current Hematologic Malignancy Reports

JF - Current Hematologic Malignancy Reports

SN - 1558-8211

IS - 2

ER -